Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.
Our lead programs include a Tie2 activator for diabetic retinopathy (DR) and a hypoxia-inducible factor 1-α (HIF-1-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie2 program, AKB-9778, recently completed a proof-of-concept, phase 2a study (TIME-2). AKB-4924, the lead compound in our and the HIF-1-α stabilization program, has recently completed a Phase 1a study.Learn more...
6/13/16 - Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 TrialRead the press release.
11/17/15 - Aerpio Therapeutics Reports Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 TrialRead the press release.
10/9/15 - Aerpio Therapeutics to Present TIME-2 Phase 2a Study of AKB-9778 in Diabetic Macular Edema Data at 2015 American Academy of Ophthalmology Annual Meeting Retina Subspecialty DayRead the press release.